MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:January 20, 2023 Post category:Press Release
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc. Post published:December 12, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:December 9, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO Post published:September 24, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:September 15, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS Post published:August 12, 2022 Post category:Press Release
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Post published:July 20, 2022 Post category:Press Release
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation Post published:June 17, 2022 Post category:Press Release
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update Post published:April 1, 2022 Post category:Press Release